News coverage about Emergent Biosolutions (NYSE:EBS) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Emergent Biosolutions earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 47.1025846980532 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s rankings:
- Aberdeen Asset Management PLC/UK Raises Its Holdings in Emergent Biosolutions, Inc. (EBS) Stock Last Quarter - Modern Readers (modernreaders.com)
- Emergent BioSolutions Inc. (EBS) and Cambrex Corporation (CBM) Go Head-to-head - StockNewsGazette (stocknewsgazette.com)
- Biotech movers: Ionis Drops After GSK Bows Out of Partnership (finance.yahoo.com)
- Emergent Biosolutions Inc (NYSE:EBS) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- Emergent BioSolutions Inc (EBS) CMF Showing Increased Buying Pressure - Evergreen Caller (evergreencaller.com)
EBS has been the topic of several recent research reports. Zacks Investment Research cut shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. BidaskClub raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Emergent Biosolutions presently has a consensus rating of “Hold” and a consensus target price of $44.00.
Shares of Emergent Biosolutions (NYSE EBS) traded up 1.08% during midday trading on Friday, reaching $34.51. 222,401 shares of the company’s stock traded hands. Emergent Biosolutions has a 52 week low of $24.47 and a 52 week high of $36.95. The stock’s 50 day moving average is $34.85 and its 200-day moving average is $31.50. The company has a market capitalization of $1.42 billion, a PE ratio of 21.98 and a beta of 1.22.
Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by $0.13. The company had revenue of $100.77 million for the quarter, compared to analyst estimates of $111.57 million. Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period last year, the firm earned ($0.05) earnings per share. On average, analysts forecast that Emergent Biosolutions will post $1.55 earnings per share for the current fiscal year.
In related news, Chairman Fuad El-Hibri sold 25,000 shares of the company’s stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $36.50, for a total transaction of $912,500.00. Following the transaction, the chairman now directly owns 1,630,216 shares of the company’s stock, valued at $59,502,884. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 16.50% of the stock is currently owned by insiders.
WARNING: This news story was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2017/08/13/emergent-biosolutions-ebs-receives-media-sentiment-score-of-0-07.html.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
